v3.26.1
Acquisitions - Narrative (Details)
$ in Thousands
3 Months Ended
Jul. 08, 2025
USD ($)
Jan. 08, 2025
USD ($)
arrangement
Mar. 31, 2026
USD ($)
Mar. 31, 2025
USD ($)
Dec. 31, 2025
USD ($)
Aug. 07, 2025
USD ($)
Business Combination [Line Items]            
Revenue     $ 3,500 $ 2,500    
Holdback     1,000 0    
Business combination, additional consideration payable     4,183   $ 5,684  
Call Option            
Business Combination [Line Items]            
Stock available for repurchase   $ 10,000        
Option contract period   5 years        
Redemption requirement, revenue threshold   $ 5,000        
Akoya Biosciences, Inc.            
Business Combination [Line Items]            
Contract with customer, unfavorable terms           $ 16,700
Indefinite-lived intangible assets: $ 121,800          
Revenue     21,600      
Contract with customer, non-cash revenue recognized     13,700      
Deferred revenue     7,900      
Business combination, acquisition-related cost, expense     0 0    
Total fair value of consideration transferred 150,973          
Cash paid for debt extinguishment $ 82,131          
Akoya Biosciences, Inc. | In Process Research and Development            
Business Combination [Line Items]            
Indefinite-lived intangible assets:     $ 19,300      
Emission            
Business Combination [Line Items]            
Total fair value of consideration transferred   16,600        
Holdback   $ 1,000        
Number of contingent consideration arrangements | arrangement   2        
Cash paid for debt extinguishment   $ 6,600        
Emission | Earnout 1            
Business Combination [Line Items]            
Additional consideration         $ 10,000  
Business combination, additional consideration payable       $ 3,700    
Emission | Earnout 2            
Business Combination [Line Items]            
Additional consideration   $ 50,000        
Performance period   5 years